Hypofractionated radiotherapy results of patients with malign glioma aged 60 and over

Gülçin ERTAŞ; Ali Rıza ÜÇER; Can AZAK; Muzaffer Bedri ALTUNDAĞ

doi:https://doi.org/10.32322/jhsm.975342

Makale detayları

Hypofractionated radiotherapy results of patients with malign glioma aged 60 and over

Yazarlar:

Gülçin ERTAŞ | Ali Rıza ÜÇER | Can AZAK | Muzaffer Bedri ALTUNDAĞ

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2021 Vol.4 Issue 6, pp.871-875

Belge Tipi:

Makale

Yayın Tarihi:

9/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000481828

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.975342

Özet:

 

Aim:  The aim of this study is to examine the treatment results of 25 malign glioma patients, aged >60 who underwent hypofractionated radiotherapy, respectively.
Material and Method: Total excision was applied to 14 of the patients, subtotal excision was applied to 5 and biopsy was applied only to 3. Three patients were evaluated as inoperable. Pathological diagnosis is compatible with glioblastoma in 22 patients, gliosarcoma in 2 patients and anaplastic astrocytoma in 1 patient. Hypofractionated radiotherapy was applied to all patients in the dose range 2.66-3.4 Gy x 10-15 fractions. Ten patients were treated concurrent temozolomide with radiotherapy and then 4-6 cures of adjuvant temozolomide. Only concurrent temozolomide treatment was applied to 3 patients, while only adjuvant temozolomide was applied to 4 patients.
Results: The median age is 72 years. (min 60–max 86) . The rate of patients with comorbid disease is 44%. The median follow-up period of the patients is 5 months (min 1-max 22). 6-months, 1-year, 18-months overall survival were 47%, 20%, 10%, respectively. Median survival in patients aged >70 is 3 months and 8 months in patients <70 (p=0.025). Median survival is 10 months in patients receiving both concurrent and adjuvant temozolomide treatment, and median survival is 3 months (p=0.007) in patients who do not receive it. 
Conclusion:  Overall survival is statistically better in patients under the age of 70 and patients receiving both concurrent and adjuvant temozolomide therapy with hypofractionated radiotherapy.

Makale detayları

Hypofractionated radiotherapy results of patients with malign glioma aged 60 and over

Yazarlar: Gülçin ERTAŞ | Ali Rıza ÜÇER | Can AZAK | Muzaffer Bedri ALTUNDAĞ

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Sağlık teşvikleri

Dergi: Journal of Health Sciences and Medicine 2021 Vol.4 Issue 6, pp.871-875

Belge Tipi: Makale

Yayın Tarihi: 9/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000481828

Sıklık: İki Aylık

eISSN: 2636-8579

DOI: https://doi.org/10.32322/jhsm.975342

Sayı

Yazarlar:

Gülçin ERTAŞ | Ali Rıza ÜÇER | Can AZAK | Muzaffer Bedri ALTUNDAĞ

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Journal of Health Sciences and Medicine 2021 Vol.4 Issue 6, pp.871-875

Belge Tipi:

Makale

Yayın Tarihi:

9/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000481828

Sıklık:

İki Aylık

eISSN:

2636-8579

DOI:

https://doi.org/10.32322/jhsm.975342